One limitation of our study is that it relies on a small cohort of breast cancer patients who were treated between 2004 and 2010, an era before immunotherapy and before neoadjuvant anti-HER2 therapy, which might affect the DFS and OS. The gene discussed is ERBB2; the disease is breast cancer.